If you cannot see this email please follow this link.
Newsletter Regulatory Affairs
Your monthly regulatory affairs update
{Anrede},

Welcome to the  October 2023 issue of the regulatory affairs newsletter.

Today you will receive an overview of regulatory issues of the last few weeks and a summary of the Online PharmaFORUM on the topic of "Drug co-distribution: PV challenges".
Editorial
News from EMA
News from European Commission
News from BfArM and PEI
Monthly reports
Online PharmaFORUM – "Drug co-distribution: PV challenges"

Author: Dr C. Michaela Gottwald, FORUM Institut für Management GmbH

On September 15, 2023, the Online PharmaFORUM took place on the topic of "Drug co-distribution: PV challenges". The speakers Dr Christian Moers and Dr Axel Thiele explained the basics of drug co-distribution and highlighted the specific requirements with regards to pharmacovigilance. ... more
News from EMA
EMA and EUnetHTA have published the report on the implementation of the EMA-EUnetHTA 21 workplan 2021 – 2023.
Details


EMA has updated the "IRIS guide for applicants" on 3rd October.
Details

You are interested in an update on the latest electronic submission necessities including usage of the EMA-IRIS-portal? More information on our German language seminar “eSubmission - Ihre To-dos 2023” can be found here.
Details



EMA has updated the guidance on "pre-authorisation procedural advice for users of the centralised procedure" on 29th September.
Details


PharmaFORUM Webcast International - More information >>


News from European Commission
The European Parliament initiates the legislative process for the EU pharmaceutical package. On September 20, the ENVI Committee (Committee on Environment, Public Health, and Food Safety) in the European Parliament held a joint debate on the pharmaceutical package, engaging in a discussion with the Commission. The recording of the meeting can be watched here.
Details

The changes in the EU pharmaceutical legislation will have far-reaching implications for various aspects of European drug approval procedures. With a strategic regulatory approach, you can significantly expedite authorization processes in the future, streamline your work efficiently, and manage maintenance activities faster. You want to update yourself operationally and strategically to the latest standards and the potential changes in EU pharmaceutical legislation? More information on our German language seminar “EU Pharmaceutical Legislation - Konsequenzen für Ihre Regulatory Strategy” can be found here.
Details



News from BfArM and PEI
German BfArM announces changes according to § 5 of the Package Size Regulation.
Details


PharmaFORUM Webcast Biologics - More information >>


Monthly reports
PRAC:
Details


CHMP:
Details


CMDh:
Details


CVMP:
Details

Kind regards,

Dr Rebekka Bitsch
Your contact for
Regulatory Affairs (Human)
+49 6221 500-565
Dr C. Michaela Gottwald
Your contact for
Regulatory Affairs (Veterinary)
+49 6221 500-610
Dr Birgit Wessels
Your contact for
Quality, Safety, CMC
+49 6221 500-652


TO UNSUBSCRIBE:
If you do not want to receive this information in future, you can unsubscribe here!
FORUM ⋅ Institut für Management GmbH ⋅ Vangerowstr. 18 ⋅ 69115 Heidelberg ⋅ Germany
Fon +49 6221 500-500 ⋅ Fax +49 6221 500-555 ⋅ service@forum-institut.de www.forum-institut.com
Copyright 2023 FORUM ⋅ Institut für Management GmbH
Imprint, privacy policy, terms and conditions